Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Breast cancer prevention in high-risk post-menopausal women

Prof Jack Cuzick - Queen Mary University of London, London, UK
Breast cancer prevention in high-risk post-menopausal women ( Prof Jack Cuzick - Queen Mary University of London, London, UK )
18 Dec 2019

Accelerated partial breast irradiation versus whole breast irradiation in patients with early breast cancer

Dr Icro Meattini - Univerity of Florence, Florence, Italy
Accelerated partial breast irradiation versus whole breast irradiation in patients with early breast cancer ( Dr Icro Meattini - Univerity of Florence, Florence, Italy )
18 Dec 2019

Evaluating the combination of atezolizumab with neoadjuvant chemotherapy for the treatment of triple-negative breast cancer

Dr Luca Gianni - San Raffaele Hospital, Milan, Italy
Evaluating the combination of atezolizumab with neoadjuvant chemotherapy for the treatment of triple-negative breast cancer ( Dr Luca Gianni -  San Raffaele Hospital, Milan, Italy )
18 Dec 2019

Preventative effects of anastrozole in post-menopausal women who are at high-risk for developing breast cancer

Prof Jack Cuzick - Queen Mary University of London, London, UK
Preventative effects of anastrozole in post-menopausal women who are at high-risk for developing breast cancer ( Prof Jack Cuzick - Queen Mary University of London, London, UK )
18 Dec 2019

How effective is accelerated partial breast irradiation in patients with early breast cancer?

Dr Icro Meattini - Univerity of Florence, Florence, Italy
How effective is accelerated partial breast irradiation in patients with early breast cancer? ( Dr Icro Meattini - Univerity of Florence, Florence, Italy )
18 Dec 2019

Predicting disease recurrence in patients with early triple-negative breast cancer using circulating tumour DNA

Dr Milan Radovich - Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, USA
Predicting disease recurrence in patients with early triple-negative breast cancer using circulating tumour DNA ( Dr Milan Radovich - Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, USA )
18 Dec 2019

The emerging role of immunotherapy for the treatment of early and advanced breast cancer

Dr Rita Nanda - UChicago Medicine, Chicago, USA
The emerging role of immunotherapy for the treatment of early and advanced breast cancer ( Dr Rita Nanda - UChicago Medicine, Chicago, USA )
18 Dec 2019

APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with operable HER2-positive early breast cancer

Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium
APHINITY: Adding pertuzumab to trastuzumab plus chemotherapy in patients with operable HER2-positive early breast cancer ( Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium )
18 Dec 2019

Breast cancer incidence in post-menopausal women: Long-term influence of oestrogen plus progestin versus oestrogen alone

Prof Rowan Chlebowski - City of Hope National Medical Center, Duarte, USA
Breast cancer incidence in post-menopausal women: Long-term influence of oestrogen plus progestin versus oestrogen alone ( Prof Rowan Chlebowski - City of Hope National Medical Center, Duarte, USA )
18 Dec 2019

Could trastuzumab deruxtecan become the new standard of care for pretreated HER2-positive breast cancer patients?

Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA
Could trastuzumab deruxtecan become the new standard of care for pretreated HER2-positive breast cancer patients? ( Dr Ian Krop - Dana Farber Cancer Institute, Boston, USA )
18 Dec 2019

Addition of S-1 to post-operative endocrine therapy for patients with hormone receptor-positive HER2-negative breast cancer

Prof Masakazu Toi - Kyoto University, Kyoto, Japan
Addition of S-1 to post-operative endocrine therapy for patients with hormone receptor-positive HER2-negative breast cancer ( Prof Masakazu Toi - Kyoto University, Kyoto, Japan )
18 Dec 2019

Pertuzumab plus trastuzumab and chemotherapy continues to show benefit in HER2-positive breast cancer

Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium
Pertuzumab plus trastuzumab and chemotherapy continues to show benefit in HER2-positive breast cancer ( Prof Martine Piccart - Université Libre de Bruxelles, Brussels, Belgium )
18 Dec 2019